NCT06470750Completed
Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)
Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Advanced Prostate Cancer (CaP)
Source: ClinicalTrials.gov · Last updated 3 Sept 2026
Brief summary (registry, in English)
This study evaluates the possibility of patient-centered home care as a new model of cancer care to reduce disparities and improve health related quality of life and patient-reported outcomes in Black patients with prostate cancer.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 75 (actual)
- First submitted
- 18 Jun 2024
- Start date
- 25 Jul 2024
- Primary completion date
- 29 Sept 2025
- Lead sponsor
- Mayo Clinic
- Diseases
- Prostate cancer
- NCT number
- NCT06470750
What you commit to
- Study type: Observational
- Participants enrolled: 75
- From 25 Jul 2024 to the primary completion date, 29 Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- GROUP 1 SURVEYS:
- Do not identify as Black men
- Have not been diagnosed with prostate cancer
- GROUP 2:
- Do not identify as Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges)
- Have not been diagnosed with histologic evidence of prostate adenocarcinoma
- Are not requiring active standard anti-cancer therapy
Other
- GROUP 1 FOCUS GROUPS:
- Individuals who do not identify as Black or male or who have had no extensive interaction with the healthcare system
- GROUP 1 INTERVIEWS:
- Not enrolled in the survey phase of the protocol
Who the study is looking for
- GROUP 1 FOCUS GROUPS:
- Individuals identifying as Black and male who are familiar with the landscape of medical care and cancer
- GROUP 1 SURVEYS:
- Are 18 years of age or older
- Have histologic evidence of prostate adenocarcinoma
- Are requiring, have required, or will require prostate cancer treatment
- Have an understanding of the protocol and its requirements
- Are willing to fill in a questionnaire and participate in a focused interview
- Are able and willing to sign an informed consent
- GROUP 1 INTERVIEWS:
- Enrollment in the survey phase of the protocol
- GROUP 2:
- Are 18 years of age or older
- Are Black men or other discounted patients (older adults, individuals residing in rural or remote areas, and those facing transportation challenges)
- Have histologic evidence of prostate adenocarcinoma
- Are requiring active standard hormone-based therapies (degarelix or leuprolide), antibone resorptive agents (zoledronic acid or denosumab), oral anticancer treatments (abiraterone or second-generation androgen receptor blockers) or intravenous chemotherapy (docetaxel)
- Are receiving part of supportive care/symptom management and/or anti-cancer therapy in the home as part of Cancer Care Beyond Walls (CCBW)
- Have an understanding of the protocol and its requirements
- Are able and willing to sign informed consent
Age in the registry: 18 years to - · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Florida Coordinator of this site? Confirm its status | Jacksonville | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.